Rybelsus and A1C reduction The PIONEER 4 (Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial) study conducted a trial with 711 adult participants, all with Type 2 Diabetes
In performance, consistency beats intensity
We examined the psychometric properties of the first factor extracted from the somatic FF, HAMA, and HAMD scores as well as the affective HAMD and HAMA scores in order to determine if it is possible to construct a latent vector score that adequately reflects the overall neuropsychiatric symptoms (combining somatic and mental symptoms) [25, 26]
Neurosci., 28, 13876 13888 11
Wang Z, Yang L
At the 12 mg dose, participants experienced an average 86% reduction in liver fat over 48 weeks